What is Editas Medicine, Inc. (EDIT) stock price today?

Editas Medicine, Inc. (EDIT) is currently trading at $2.95, up 4.04% today.

What is EDIT P/E ratio?

Editas Medicine, Inc.'s P/E ratio is -3.50. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is EDIT return on equity (ROE)?

Editas Medicine, Inc.'s return on equity (ROE) is -196.63%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Editas Medicine, Inc.'s market cap?

Editas Medicine, Inc. has a market capitalization of $453.45M.

NASDAQ · Biotechnology

Editas Medicine, Inc. (EDIT) Stock

$2.95 +4.04% NASDAQ: EDIT Healthcare

Valuation

Metric	Value
Price	$2.95
Market Cap	$453.45M
P/E Ratio	-3.50
P/B Ratio	2.97
P/S Ratio	8.55
EPS (TTM)	$-1.80
52-Week High	$4.54
52-Week Low	$1.66
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-196.63%
ROA	-31.15%
ROCE	-48.61%
Gross Margin	-241.46%
Operating Margin	-241.46%
Net Margin	-157.32%
Debt/Equity	0.15
Current Ratio	3.57

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$26.0M	$20.0M	$78.0M	$32.0M	$41.0M
Operating Profit	$-193.0M	$-226.0M	$-169.0M	$-251.0M	$-99.0M
Net Profit	$-193.0M	$-220.0M	$-153.0M	$-237.0M	$-160.0M
EPS	$-2.85	$-3.21	$-2.02	$-2.88	$-1.80
Op Margin	-756.1%	-1146.3%	-216.6%	-777.2%	-245.2%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$677.0M	$514.0M	$499.0M	$342.0M	$187.0M
Total Liabilities	$124.0M	$154.0M	$150.0M	$207.0M	$159.0M
Cash	$204.0M	$142.0M	$124.0M	$132.0M	$147.0M
Borrowings	$26.0M	$44.0M	$49.0M	$35.0M	$77.0M

Latest News

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? Zacks · Jun 4, 2026 CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? Motley Fool · May 31, 2026 Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference GlobeNewswire · May 28, 2026 Editas Medicine Prices Public Offering of Shares, Warrants MT Newswires · May 26, 2026 Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-164.0M	$-177.0M	$-132.0M	$-210.0M	$-165.0M
Investing Cash Flow	$-62.0M	$110.0M	$-8.0M	$153.0M	$138.0M
Financing Cash Flow	$33.0M	$0	$1.0M	$0	$0
Net Cash Flow	$64.0M	$-62.0M	$-18.0M	$8.0M	$14.0M
Free Cash Flow	$-172.0M	$-181.0M	$-137.0M	$-219.0M	$-166.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.02
EV / EBITDA	-3.36
FCF Yield	-29.98%
Quick Ratio	3.19
Interest Coverage	39.05
Return 1Y	-21.10%
Return 3Y	-68.48%
Return 5Y	-92.47%

Ownership

Insiders Held0.17%

Institutions Held49.30%

Institutions Float Held49.38%

Institutional Holder	Shares	Report Date
Blackrock Inc.	9,263,312	2026-03-31
Vanguard Capital Management LLC	4,204,369	2026-03-31
Renaissance Technologies, LLC	3,972,160	2026-03-31
Vanguard Portfolio Management LLC	3,148,570	2026-03-31
Geode Capital Management, LLC	2,311,789	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BEAMBeam Therapeutics Inc.	$25.90	+5.30%	-29.88	$2.67B	0.00%
BNTCBenitec Biopharma Inc.	$8.87	+1.37%	-9.79	$304.72M	0.00%
CRBUCaribou Biosciences, Inc.	$0.48	-0.52%	-1.13	$47.48M	0.00%
CRSPCRISPR Therapeutics AG	$53.39	+5.85%	-11.62	$5.15B	0.00%
DTILPrecision BioSciences, Inc.	$6.79	+5.52%	-2.26	$187.28M	0.00%

About Editas Medicine, Inc.

Editas Medicine, Inc. is led by CEO Gilmore O'Neill, employs 246 people, headquartered in US, publicly traded since 2016.

Editas Medicine, Inc. (EDIT) stock trades at $2.95 with a market capitalization of $453.45M. The stock is valued at a price-to-earnings (P/E) ratio of -3.50, price-to-book of 2.97, price-to-sales of 8.55. Over the past 52 weeks the stock has ranged between $1.66 and $4.54, and currently trades 35.0% below its 52-week high.

On profitability, Editas Medicine, Inc. generates a return on equity (ROE) of -196.63%, return on capital employed of -48.61%, an operating margin of -241.46%, a net profit margin of -157.32%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides